Fluid Biomed Achieves Coveted ISO 13485:2016 Quality Management System Certification
JUL 14 2022 | CALGARY, AB
Fluid Biomed Inc., developer of the world’s first bio-resorbable stent to cure brain aneurysms, announces it has received ISO 13485:2016 certification, the internationally recognized benchmark for Quality Management Systems (QMS) specific to medical devices.
“Fluid Biomed is committed to better health and quality of life through innovation, and we are developing unique life-saving technologies that are safe and effective,” said Dr. John Wong, Chief Executive Officer. “Although a young company, the team has individually and collectively dedicated themselves to nurturing and supporting a culture of quality focused on continuous improvement. We’re so proud to share that our Quality Management System has been independently audited by the leading national standards body, BSI, and is now certified to the rigorous and exacting requirements of ISO 13485:2016.”
ISO 13485 is the prevailing process-based QMS standard for the medical device industry around the world. Fluid Biomed holds certificate number FM 762811 and its QMS complies with the standards of ISO 13485:2016 for the design and development of intracranial stents and associated delivery components.
Fluid Biotech Announces Rebranding, Changes Name to Fluid Biomed
JAN 20 2022 | CALGARY, AB
Fluid Biotech, a life sciences company based in Calgary, Alberta, Canada that is pioneering stent technology, is rebranding itself to Fluid Biomed, to emphasize its focus on medical device innovation as it accelerates towards clinical trials.
“Fueled by our previous over-subscribed seed financing round, we’ve made tremendous progress as a young firm in the pre-clinical testing of our flagship product: the world’s first bio-absorbable flow-diverting stent to cure the deadly disease of brain aneurysms,” states company co-founder and CEO, Dr. John Wong. “The new company name aligns with our mission of developing the next generation of stents to improve patient well-being and will help us harmonize with strategic medical device manufacturers and financial partners as we enter the next exciting phase of growth”. All other facets of the company remain unchanged and the transition is anticipated to be complete by end of Q1 2022.
Fluid Biotech Inc. Raises $4.7M USD in Oversubscribed Seed Funding Round
AUG 11 2021, 06:00 ET | PR NEWSWIRE
Fluid Biotech Secures $5.8 Million CAD to Accelerate Development of Innovative Brain Aneurysm Stent
AUG 11 2021 | BETAKIT
ORIGINAL RESEARCH: A novel self-expanding primarily bioabsorbable braided flow-diverting stent for aneurysms: initial safety results
Nov 27 2019 | JNIS
Fluid Biotech Inc. Publishes Research and Featured in Neuro News, Reaches Deign Freeze Milestone, and Adds Dr. Vitor Pereira to Advisory Board.
MAY 8 2020 | CALGARY, AB
EDITORIAL: Endovascular Stents – Do They Need To Be Permanent?
Mar 19 2020 | SCIENCE DIRECT
Self-expanding bioabsorbable flow-diverting stent shows a favourable safety profile
JAN 14 2020 | NEURO NEWS
UCalgary researchers aim to revolutionize treatment for brain aneurysms
Mar 3 2021 | UNIVERSITY OF CALGARY
“There’s no reason why we can’t leverage what we have learned and created to combat other serious diseases.” — Dr. John Wong
Fluid Biotech wins W21C Innovation Academy
OCT 31 2019 | INNOVATION ACADEMY
Fluid Biotech Wins TENET i2C Competition
JUN 12 2019 | UNIVERSITY OF CALGARY
Fluid Biotech Closes Pre-Seed Raise and add Dr. William Hunter to Advisory Board
FEB 7 2020 | CALGARY, AB